Recently, Petean et al. (2021) [10] evaluated the efficacy of systemic use of selective and non-selective inhibitors of cyclooxygenase-2 enzymes in the treatment of experimental apical periodontitis induced by bacterial lipopolysaccharide (LPS) in vivo in a mouse model, and the results demonstrated promising results with the use of COX-2 inhibitor Celecoxib, which dampened osteoclastogenic signaling, and activity that suppressed bone resorption. This evidence concerns the gene PTGS2 and periapical periodontitis.